このエピソードについて
In this episode of Pharma Explained, by Pharma Now, we look at a draft rule from India’s Health Ministry that would suspend a drug factory’s licence the moment its medicine fails one of five key quality tests. Today, a failed lab report leads to a notice, a reply and a wait, and the medicine can stay on shelves in the meantime. We explain what the draft says, why the ministry wants to change this, and why some may worry about acting on a single lab result. We also look at why the solvents used in syrups are getting a paperwork trail of their own.
We’ll cover:
- How the current process works after a medicine fails a test.
- What the draft rule would change.
- Why supporters and critics see it differently.
- What it could mean for patients, and what we still don’t know.
- Why solvents used in syrups are getting extra checks.
For the detailed stories, with sources and full numbers, visit the Pharma Now website and mobile app.
Follow Pharma Now’s social handles:
- LinkedIn: https://www.linkedin.com/company/pharma-now/?viewAsMember=true
- Facebook: https://www.facebook.com/profile.php?id=61559659700692
- X: https://x.com/PharmaNowGlobal
- Instagram: https://www.instagram.com/pharmanow.live/
Note: This content is for informational purposes only and is not medical advice. Talk to your doctor or pharmacist about your own treatment. None of the companies or products mentioned are recommendations or endorsements.